共 58 条
[1]
Hoeg JM(1987)3-Hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors in the treatment of hypercholesterolemia [J] JAMA 258 3532-6
[2]
Brewer HJ(1989)Lipid lowering drugs in atherosclerosis–the HMG-CoA reductase inhibitors [J] Clin Exp Hypertens A 11 927-41
[3]
Mantell G(1995)Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia[J] Ann Pharmacother 29 743-59
[4]
Hsu I(1995)Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program [J] Circulation 92 2419-25
[5]
Spinler SA(1999)Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial [J] Circulation 99 3227-33
[6]
Johnson NE(2007)Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease[J] Wien Med Wochenschr 157 73-8
[7]
Byington RP(2008)Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases[J] Hear Vessel 23 249-56
[8]
Jukema JW(2008)The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials [J] CMAJ 178 576-84
[9]
Salonen JT(2010)Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials[J] Lancet 376 1670-81
[10]
Dupuis J(2007)Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study) [J] Am J Cardiol 99 632-5